Related Experiment Videos
Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma
Kaiyi Li1, Shiaw-Yih Lin, F Charles Brunicardi
1Department of Surgery, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA. kli@bcm.tmc.edu
Abstract:
RNA interference is the process by which double-stranded RNA directs sequence-specific degradation of mRNA. It has recently been shown that RNA interference can be triggered by 21-nucleotide duplexes of small interfering RNAs (siRNAs) in both cultured mammalian cells and adult mice. We hypothesize that siRNA can be used to specifically target oncogene overexpression in a therapeutic manner. Here, we show that overexpression of the oncogene cyclin E can be suppressed by up to 90% in hepatocellular carcinoma (HCC) cell lines by siRNA targeted on the coding region of cyclin E. We also find that depletion of cyclin E in this manner promotes apoptosis of HCC cells and blocks cell proliferation. Finally, we show that the siRNA oligos inhibits HCC tumor growth in nude mice. Thus, this study demonstrates the therapeutic potential of siRNA on the treatment of HCC by targeting overexpressed oncogenes such as cyclin E. Our results also indicate that cyclin E, which is overexpressed in 70% of HCCs, may serve as a novel therapeutic target.
Insights
Small interfering RNA (siRNA) therapy effectively suppresses oncogene cyclin E in liver cancer cells. This approach inhibits tumor growth and offers a potential new treatment for hepatocellular carcinoma (HCC).
Area of Science:
- Molecular Biology
- Oncology
- RNA Therapeutics
Background:
- RNA interference (RNAi) is a biological process involving double-stranded RNA that leads to sequence-specific messenger RNA (mRNA) degradation.
- Small interfering RNAs (siRNAs), 21-nucleotide duplexes, have been shown to trigger RNAi in mammalian cells and in vivo.
- Oncogene overexpression is a hallmark of many cancers, including hepatocellular carcinoma (HCC).
Purpose of the Study:
- To investigate the therapeutic potential of siRNA targeting the oncogene cyclin E in hepatocellular carcinoma (HCC).
- To determine if siRNA-mediated suppression of cyclin E can inhibit HCC cell proliferation and induce apoptosis.
- To evaluate the efficacy of siRNA in reducing HCC tumor growth in a preclinical mouse model.
Main Methods:
- Hepatocellular carcinoma (HCC) cell lines were treated with siRNAs specifically designed to target the coding region of the cyclin E oncogene.
- The percentage of cyclin E suppression was quantified using molecular assays.
- Apoptosis, cell proliferation, and tumor growth in nude mice were assessed following siRNA treatment.
Main Results:
- siRNA treatment suppressed cyclin E overexpression by up to 90% in HCC cell lines.
- Depletion of cyclin E using siRNA promoted apoptosis and inhibited cell proliferation in HCC cells.
- Administration of siRNA oligos significantly inhibited HCC tumor growth in nude mice.
Conclusions:
- siRNA targeting of overexpressed oncogenes, such as cyclin E, demonstrates significant therapeutic potential for treating hepatocellular carcinoma (HCC).
- Cyclin E, frequently overexpressed in HCC, represents a promising novel therapeutic target for siRNA-based cancer therapies.
- These findings support the development of siRNA as a targeted therapy for HCC and potentially other cancers driven by oncogene overexpression.